每年研究成果
個人檔案
學歷
- 中山醫學院醫學系學士
經歷
- 1992年08月 ~迄今 胃腸肝膽科醫師
指紋 查看啟用 Pin-Nan Cheng 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
- 29 類似的檔案
Chronic Hepatitis C
Medicine & Life Sciences
Hepacivirus
Medicine & Life Sciences
Chronic Hepatitis B
Medicine & Life Sciences
Virus Diseases
Medicine & Life Sciences
Ribavirin
Medicine & Life Sciences
Genotype
Medicine & Life Sciences
Hepatitis B virus
Medicine & Life Sciences
Taiwan
Medicine & Life Sciences
網絡
國家層面的近期外部合作。點選圓點深入探索詳細資料。
研究成果 1996 2019
An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions
Huang, C. F., Hung, C. H., Cheng, P. N., Bair, M. J., Huang, Y. H., Kao, J. H., Hsu, S. J., Lee, P. L., Chen, J. J., Chien, R. N., Peng, C. Y., Lin, C. Y., Hsieh, T. Y., Cheng, C. H., Dai, C. Y., Huang, J. F., Chuang, W. L. & Yu, M. L., 2019 七月 19, 於 : The Journal of infectious diseases. 220, 4, p. 557-566 10 p.研究成果: Article
Chronic Hepatitis C
Viral Load
Fibrosis
Randomized Controlled Trials
Genotype
1
引文
(Scopus)
Augmenting central arterial stiffness following eradication of HCV by direct acting antivirals in advanced fibrosis patients
Cheng, P-N., Chen, Z-Y., Chiu, Y-C., Chiu, H-C. & Tsai, L-M., 2019 十二月 1, 於 : Scientific reports. 9, 1, 1426.研究成果: Article
Vascular Stiffness
Antiviral Agents
Fibrosis
Chronic Hepatitis C
Blood Pressure
Combined transarterial embolization/ chemoembolization-based locoregional treatment with sorafenib prolongs the survival in patients with advanced hepatocellular carcinoma and preserved liver function: A propensity score matching study
Chien, S. C., Chen, C-Y., Cheng, P-N., Liu, Y. S., Cheng, H-C., Chuang, C-H., Chang, T-T., Chiu, H. C., Lin, Y-J. & Chiu, Y-C., 2019 一月 1, 於 : Liver Cancer. 8, 3, p. 186-202 17 p.研究成果: Article
Propensity Score
Hepatocellular Carcinoma
Survival
Liver
Liver Neoplasms
2
引文
(Scopus)
Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions
Yu, M. L., Hung, C. H., Huang, Y. H., Peng, C. Y., Lin, C. Y., Cheng, P-N., Chien, R. N., Hsu, S. J., Liu, C. H., Huang, C. F., Su, C. W., Huang, J. F., Liu, C. J., Kao, J. H., Chuang, W. L., Chen, P. J. & Chen, D. S., 2019 二月 1, 於 : Journal of the Formosan Medical Association. 118, 2, p. 556-564 9 p.研究成果: Article
開啟存取
Ribavirin
Genotype
Safety
Infection
Galectin 3
2
引文
(Scopus)
Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia–Pacific region and Russia: Final results from the randomized C-CORAL study
on behalf of the C-CORAL Investigators, 2019 一月, 於 : Journal of Gastroenterology and Hepatology (Australia). 34, 1, p. 12-21 10 p.研究成果: Article
開啟存取
Russia
Hepacivirus
Genotype
Safety
Infection